Metformin immediate release (IR)

DRUG2 trials

Sponsors

AstraZeneca

Conditions

Type 2 DiabetesType 2 Diabetes Mellitus

Phase 1

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

TerminatedNCT01525225

AstraZenecaType 2 Diabetes Mellitus

Start: 2012-09-30End: 2013-06-30Updated: 2015-06-22

Phase 3

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

CompletedNCT01646320

AstraZenecaType 2 Diabetes

Start: 2012-09-30End: 2015-02-28Updated: 2016-06-22

Related Papers

Characterization of the Open-Label Lead-In Period of Two Randomized Controlled Phase 3 Trials Evaluating Dapagliflozin, Saxagliptin, and Metformin in Type 2 Diabetes.

2018-05-255 citations

Dreifachtherapie mit Dapagliflozin (DAPA) als Add-on zu Saxagliptin (SAXA) plus Metformin (MET): Analyse der offenen SAXA+MET-Vorlaufzeit einer Phase-3-Studie

Diabetologie und Stoffwechsel2016-04-19